FA
ATNM icon

FCG Advisors’s Actinium Pharmaceuticals ATNM Stock Holding History

FCG Advisors’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,257
Closed -$13K – 189
2020
Q2 		$13K Hold
1,257
– – ﹤0.01% 168
2020
Q1 		$7K Hold
1,257
– – ﹤0.01% 159
2019
Q4 		$8K Buy
+1,257
New +$8.67K ﹤0.01% 165

Other funds holding ATNM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

FCG Advisors's ATNM Position: Q3 2020 in Review

FCG Advisors sold out of Actinium Pharmaceuticals (ATNM) in Q3 2020, closing a stake of 1,257 shares — an estimated $13K sold.

FCG Advisors first reported a position in ATNM in Q4 2019 and held it in 3 quarters. The position peaked at $13K in Q2 2020. 41 funds tracked by Wall St. Rank hold ATNM as of Q3 2020.

  • FCG Advisors reported no remaining Actinium Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • FCG Advisors sold 1,257 Actinium Pharmaceuticals shares in Q3 2020, an estimated $13K.
  • FCG Advisors first reported a position in Actinium Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • FCG Advisors's Actinium Pharmaceuticals position peaked at $13K in Q2 2020.
  • 41 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2020.

Based on FCG Advisors's 13F filing for Q3 2020, filed 13 Nov 2020.